0000000000210567

AUTHOR

Caterina De Carolis

0000-0002-6597-6253

showing 3 related works from this author

International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by …

2012

Background There are a limited number of publications on the management of gynecologic/obstetric events in female patients with hereditary angioedema caused by C1 inhibitor deficiency (HAE-C1-INH). Objective We sought to elaborate guidelines for optimizing the management of gynecologic/obstetric events in female patients with HAE-C1-INH. Methods A roundtable discussion took place at the 6th C1 Inhibitor Deficiency Workshop (May 2009, Budapest, Hungary). A review of related literature in English was performed. Results Contraception : Estrogens should be avoided. Barrier methods, intrauterine devices, and progestins can be used. Pregnancy : Attenuated androgens are contraindicated and should …

Complement C1 Inactivator ProteinsAbortionCardiovascularEcallantidechemistry.chemical_compoundDelivery Obstetric; Complement C1 Inactivator Proteins; Humans; Infant Newborn; Breast Neoplasms; Genetic Counseling; Pregnancy; Lactation; Genital Diseases Female; Infant; Contraception; Hereditary Angioedema Types I and II; Menstruation; Pregnancy Complications Cardiovascular; Chemoprevention; Prenatal Diagnosis; Menopause; FemalePregnancyIcatibantPrenatal DiagnosisImmunology and AllergyfertilityHereditary Angioedema Types I and IItreatmentObstetricsVaginal deliveryMenstruationContraceptioncontraceptionGenital DiseasesHereditary angioedemaFemalepregnancyMenopausedeliverymedicine.symptomComplement C1 Inhibitor ProteinDeliverymedicine.drugmedicine.medical_specialtyPregnancy Complications CardiovascularImmunologyBreast NeoplasmsGenetic CounselingIntrauterine deviceChemopreventionbreast cancermedicineHumansLactationGynecologyPregnancygenetic counselingAngioedemabusiness.industryangioedemaInfant NewbornInfantObstetricDelivery ObstetricNewbornmedicine.diseasehereditary angioedemaPregnancy ComplicationsSettore MED/16 - ReumatologiachemistryC1 inhibitor deficiencybusinessGenital Diseases FemaleJournal of Allergy and Clinical Immunology
researchProduct

A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy

2014

Introduction Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE type I) or dysfunction (C1-INH-HAE type II) is a rare disease characterized by recurrent episodes of edema with an estimated frequency of 1:50,000 in the global population without racial or gender differences. In this study we present the results of a nationwide survey of C1-INH-HAE patients referring to 17 Italian centers, the Italian network for C1-INH-HAE, ITACA. Methods Italian patients diagnosed with C1-INH-HAE from 1973 to 2013 were included in the study. Diagnosis of C1-INH-HAE was based on family and/or personal history of recurrent angioedema without urticaria and on antigenic and/or functional C1-INH def…

AdultMalePediatricsmedicine.medical_specialtyAdolescentPopulationNationwide surveyC1-inhibitorYoung AdultmedicineHumansGenetics(clinical)C1 inhibitor; C4; Hereditary angioedema; Adolescent; Adult; Angioedemas Hereditary; Female; Humans; Italy; Male; Middle Aged; Young Adult; Medicine (all); Genetics (clinical); Pharmacology (medical)Pharmacology (medical)Young adulteducationGenetics (clinical)C4Medicine(all)Hereditary angioedemaeducation.field_of_studyC1 inhibitorAngioedemabiologybusiness.industryResearchMedicine (all)Angioedemas HereditaryAngioedemasGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseSettore MED/16 - ReumatologiaHereditaryItalyHereditary angioedemabiology.proteinFemalemedicine.symptomDifferential diagnosisbusinessRare diseaseOrphanet Journal of Rare Diseases
researchProduct

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an Inter…

2011

Angioedema owing to hereditary deficiency of C1 inhibitor (HAE) is a rare, life-threatening, disabling disease. In the last 2 years, the results of well-designed and controlled trials with existing and new therapies for this condition have been published, and new treatments reached the market. Current guidelines for the treatment for HAE were released before the new trials and before the new treatments became available and were essentially based on observational studies and expert opinion. To provide evidence-based HAE treatment guidelines supported by the new studies, a conference was held in Gargnano del Garda, Italy, from September 26 to 29, 2010. The meeting hosted 58 experienced HAE ex…

medicine.medical_specialtyEvidence-based practiceAngioedemabiologybusiness.industryImmunologyAlternative medicineLanadelumabmedicine.diseaseC1-inhibitorEcallantideFamily medicineHereditary angioedemamedicinebiology.proteinImmunology and AllergyObservational studymedicine.symptombusinessmedicine.drugAllergy
researchProduct